CNS Pharmaceuticals, Inc. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
CNS Pharmaceuticals, Inc. (CNSP) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $430.68 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2021-05-13
- CNS Pharmaceuticals, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2021-03-31 was $430.68K, a 77.81% increase year-over-year.
- CNS Pharmaceuticals, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2020-03-31 was $242.21K.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 3 month |
|---|---|
| 2021-03-31 | $430.68K 10-Q · filed 2021-05-13 |
| 2020-03-31 | $242.21K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |